FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and ...
FDA approves EBGLYSS, a new biologic treatment for moderate-to-severe atopic dermatitis, offering significant skin clearance and itch relief within weeks, with long-lasting efficacy through monthly maintenance doses.
Related Clinical Trials
Reference News
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and ...
FDA approves EBGLYSS, a new biologic treatment for moderate-to-severe atopic dermatitis, offering significant skin clearance and itch relief within weeks, with long-lasting efficacy through monthly maintenance doses.